The estimated Net Worth of Stuart Rich is at least $15.6 Millón dollars as of 11 June 2021. Dr Rich owns over 3,581,000 units of Tenax Therapeutics Inc stock worth over $15,616,143 and over the last 4 years he sold TENX stock worth over $0.
Dr has made over 1 trades of the Tenax Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 3,581,000 units of TENX stock worth $13,178,080 on 11 June 2021.
The largest trade he's ever made was exercising 3,581,000 units of Tenax Therapeutics Inc stock on 11 June 2021 worth over $13,178,080. On average, Dr trades about 596,833 units every 0 days since 2021. As of 11 June 2021 he still owns at least 4,243,517 units of Tenax Therapeutics Inc stock.
You can see the complete history of Dr Rich stock trades at the bottom of the page.
Dr. Stuart Rich M.D. is the Chairman of Scientific Advisory Board, Chief Medical Officer & Director at Tenax Therapeutics Inc.
Dr D is 71, he's been the Chairman of Scientific Advisory Board y Chief Medical Officer & Director of Tenax Therapeutics Inc since . There are 2 older and 13 younger executives at Tenax Therapeutics Inc. The oldest executive at Tenax Therapeutics Inc is Ronald Blanck, 75, who is the Independent Chairman of the Board.
Stuart's mailing address filed with the SEC is 101 GLEN LENNOX DRIVE. SUITE 300, , CHAPEL HILL, NC, 27517.
Over the last 10 years, insiders at Tenax Therapeutics Inc have traded over $5,051 worth of Tenax Therapeutics Inc stock and bought 571,282 units worth $853,236 . The most active insiders traders include Capital, Llc Armistice Capi..., Declan Doogan y Stuart Rich. On average, Tenax Therapeutics Inc executives and independent directors trade stock every 218 days with the average trade being worth of $1,664,103. The most recent stock trade was executed by Gerald T Proehl on 8 August 2024, trading 1,666 units of TENX stock currently worth $6,131.
tenax therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions. our development portfolio includes novel product candidates that have the potential to address various critical care conditions with high unmet medical need.
Tenax Therapeutics Inc executives and other stock owners filed with the SEC include: